Rice Hall James & Associates LLC Reduces Stock Holdings in Medpace Holdings, Inc. $MEDP

Rice Hall James & Associates LLC cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 91,409 shares of the company’s stock after selling 11,045 shares during the period. Medpace comprises about 2.6% of Rice Hall James & Associates LLC’s holdings, making the stock its 4th biggest position. Rice Hall James & Associates LLC’s holdings in Medpace were worth $46,999,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of MEDP. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Employees Retirement System of Texas bought a new position in Medpace during the second quarter valued at $36,000. IFP Advisors Inc increased its position in Medpace by 223.3% in the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after buying an additional 134 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of Medpace by 5,075.0% in the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after buying an additional 203 shares during the period. Finally, Cary Street Partners Investment Advisory LLC raised its stake in shares of Medpace by 514.3% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock valued at $67,000 after buying an additional 180 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $567.56 on Friday. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $626.26. The company has a fifty day moving average of $579.62 and a 200-day moving average of $480.17. The company has a market capitalization of $15.99 billion, a P/E ratio of 39.69, a P/E/G ratio of 2.16 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the previous year, the company posted $3.01 EPS. Medpace’s quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. Rothschild & Co Redburn lowered shares of Medpace from a “buy” rating to a “neutral” rating and upped their target price for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. Finally, Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $490.82.

Insider Activity

In related news, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 387,925 shares of company stock valued at $233,386,647. Insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.